SCHEMBL2379423

SCHEMBL2379423

CC(=O)N1CCN(c2ccc(B3OC(C)(C)C(C)(C)O3)cc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 5/20 0.55
CASP6 P55212 1/20 0.55
MAPT P10636 9/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
NPC1 O15118 2/20 0.45
RAB9A P51151 2/20 0.45
USP2 O75604 3/20 0.44
ALOX12 P18054 7/20 0.44
ALDH1A1 P00352 6/20 0.44
GAA P10253 6/20 0.44
ALOX15 P16050 6/20 0.44
MAPK1 P28482 4/20 0.44
CYP2C9 P11712 3/20 0.44
HPGD P15428 2/20 0.44
CYP2C19 P33261 2/20 0.44
HSD17B10 Q99714 3/20 0.44
CYP1A2 P05177 1/20 0.44
KDM4E B2RXH2 5/20 0.43
TSHR P16473 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3017161 0.95 GFER (0.50) GFERCASP6MAPTMEN1KMT2A
SCHEMBL578443 0.89 LIPG (0.44) GFERCASP6MEN1KMT2AUSP2
SCHEMBL24511506 0.87 LPL (0.42) GFERCASP6MEN1KMT2ATSHR
SCHEMBL15656543 0.85 MAPT (0.48) MAPTMEN1KMT2AALDH1A1GAA
SCHEMBL30613530 0.85 HRH3 (0.41) GFERCASP6MAPTMEN1KMT2A
SCHEMBL14167571 0.85 AKR1C3 (0.52) MAPTKMT2AALDH1A1MAPK1HTT
SCHEMBL31646075 0.85 POLB (0.42) GFERCASP6MAPTMEN1KMT2A
SCHEMBL22816582 0.84 USP2 (0.46) GFERCASP6MAPTMEN1KMT2A
SCHEMBL15656742 0.84 TDP1 (0.58) MAPTMEN1KMT2AUSP2ALOX12
SCHEMBL31485217 0.83 CYP2C19 (0.45) MEN1KMT2AUSP2ALOX12ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3768675-B1 NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORP (KR) 2026-04-01 EP disclosed
US-20250382277-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF UNIV ARIZONA (US) 2025-12-18 US disclosed
US-20250136568-A1 FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS NANJING ZENSHINE PHARMACEUTICALS CO., LTD. (CN) 2025-05-01 US disclosed
EP-4543887-A2 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF Arizona Board of Regents on behalf of The University of Arizona (US) 2025-04-30 EP disclosed
US-20250057852-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS INCYTE CORPORATION 2025-02-20 US disclosed
US-20240417392-A1 3,3-DIFLUOROALLYLAMINES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORP (KR) 2024-12-19 US disclosed
US-12122767-B2 Bicyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2024-10-22 US disclosed
EP-4444714-A1 FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS Nanjing Zenshine Pharmaceuticals Co., Ltd. (CN) 2024-10-16 EP disclosed
US-12083124-B2 Bicyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2024-09-10 US disclosed
CN-111886233-B Triazolone derivatives or salts thereof and pharmaceutical compositions containing the same 柳韩洋行 2024-01-02 CN disclosed
US-20140121200-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS HUTCHISON MEDIPHARMA LIMITED (CN) 2014-05-01 US disclosed
EP-2718293-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS Hutchison Medipharma Limited (CN) 2014-04-16 EP disclosed
WO-2013153479-A2 INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK PFIZER INC. (US) 2013-10-17 WO disclosed
US-20130267493-A1 INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK PFIZER INC. (US) 2013-10-10 US disclosed
US-8518945-B2 Pyrrolopyrazine kinase inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-08-27 US disclosed
EP-2550273-A2 PYRROLOPYRAZINE KINASE INHIBITORS F. Hoffmann-La Roche AG (CH) 2013-01-30 EP disclosed
WO-2012167733-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS HUTCHISON MEDIPHARMA LIMITED (CN) 2012-12-13 WO disclosed
WO-2012167733-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS HUTCHISON MEDIPHARMA LIMITED (CN) 2012-12-13 WO disclosed
WO-2011117145-A2 PYRROLOPYRAZINE KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2011-09-29 WO disclosed
US-20110230462-A1 Pyrrolopyrazine Kinase Inhibitors HENDRICKS ROBERT THAN 2011-09-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12083124-B2 Bicyclic heterocycles as FGFR inhibitors FGFR1, FGFR3, FGFR2 GFER 2075/4885CASP6 3845/4885MAPT 4204/4885
US-20110230462-A1 Pyrrolopyrazine Kinase Inhibitors SYK, ZAP70, BTK GFER 3232/4885CASP6 2231/4885MAPT 3798/4885
US-20250382277-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF CLK2, CLK3, CLK1 GFER 4733/4885CASP6 2683/4885MAPT 1251/4885
US-20250057852-A1 BICYCLIC HETEROCYCLES AS FGFR INHIBITORS FGFR1, FGFR3, FGFR2 GFER 2075/4885CASP6 3845/4885MAPT 4204/4885
US-20240417392-A1 3,3-DIFLUOROALLYLAMINES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME VAPA, VAPB, SLC10A1 GFER 2045/4885CASP6 3811/4885MAPT 2179/4885
US-20250136568-A1 FUSED HETEROCYCLIC COMPOUNDS AS PI3KALPHA INHIBITORS PIK3CA, PIK3CD, PIK3CB GFER 3872/4885CASP6 396/4885MAPT 4738/4885
US-20140121200-A1 SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS SYK, BTK, LYN GFER 3082/4885CASP6 2109/4885MAPT 3952/4885
US-12122767-B2 Bicyclic heterocycles as FGFR inhibitors FGFR3, FGFR1, FGFR2 GFER 2183/4885CASP6 4305/4885MAPT 3854/4885
US-20130267493-A1 INDOLE AND INDAZOLE COMPOUNDS THAT ACTIVATE AMPK PRKAG1, PRKAG3, PRKAG2 GFER 4030/4885CASP6 1986/4885MAPT 1317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.